Oasis Management proposes three paths for Kobayashi Pharmaceutical amid a scandal: self-improvement, going private, or collaborating with Oasis.
Activist investor Oasis Management proposes three paths for value creation at Kobayashi Pharmaceutical amid a scandal over its red koji-related products. Options include (i) self-improvement in operational performance, (ii) going private via management buyout, or (iii) collaborating with Oasis on operational, governance, and board improvements. The company's shares have declined over 45% since December 2020, with a 20% drop since the scandal's end in 2023.
August 10, 2024
4 Articles